Virax Biolabs Group Statistics
Total Valuation
VRAX has a market cap or net worth of $3.91 million. The enterprise value is $299,206.
Important Dates
The last earnings date was Wednesday, February 5, 2025, before market open.
| Earnings Date | Feb 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
VRAX has 4.34 million shares outstanding. The number of shares has increased by 85.92% in one year.
| Current Share Class | 4.34M |
| Shares Outstanding | 4.34M |
| Shares Change (YoY) | +85.92% |
| Shares Change (QoQ) | +40.39% |
| Owned by Insiders (%) | 10.09% |
| Owned by Institutions (%) | 1.45% |
| Float | 3.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 617.24 |
| Forward PS | n/a |
| PB Ratio | 0.69 |
| P/TBV Ratio | 0.69 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 47.26 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.27, with a Debt / Equity ratio of 0.13.
| Current Ratio | 7.27 |
| Quick Ratio | 6.47 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -105.93 |
Financial Efficiency
Return on equity (ROE) is -114.47% and return on invested capital (ROIC) is -66.76%.
| Return on Equity (ROE) | -114.47% |
| Return on Assets (ROA) | -64.68% |
| Return on Invested Capital (ROIC) | -66.76% |
| Return on Capital Employed (ROCE) | -107.11% |
| Revenue Per Employee | $333 |
| Profits Per Employee | -$319,013 |
| Employee Count | 19 |
| Asset Turnover | 0.00 |
| Inventory Turnover | 0.32 |
Taxes
| Income Tax | -136,661 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -17.43% in the last 52 weeks. The beta is 1.64, so VRAX's price volatility has been higher than the market average.
| Beta (5Y) | 1.64 |
| 52-Week Price Change | -17.43% |
| 50-Day Moving Average | 0.95 |
| 200-Day Moving Average | 1.54 |
| Relative Strength Index (RSI) | 52.16 |
| Average Volume (20 Days) | 55,742 |
Short Selling Information
The latest short interest is 17,496, so 0.40% of the outstanding shares have been sold short.
| Short Interest | 17,496 |
| Short Previous Month | 20,758 |
| Short % of Shares Out | 0.40% |
| Short % of Float | 0.48% |
| Short Ratio (days to cover) | 0.32 |
Income Statement
In the last 12 months, VRAX had revenue of $6,331 and -$6.06 million in losses. Loss per share was -$1.62.
| Revenue | 6,331 |
| Gross Profit | -53,067 |
| Operating Income | -6.16M |
| Pretax Income | -6.92M |
| Net Income | -6.06M |
| EBITDA | -5.91M |
| EBIT | -6.16M |
| Loss Per Share | -$1.62 |
Full Income StatementBalance Sheet
The company has $4.32 million in cash and $714,580 in debt, giving a net cash position of $3.61 million or $0.83 per share.
| Cash & Cash Equivalents | 4.32M |
| Total Debt | 714,580 |
| Net Cash | 3.61M |
| Net Cash Per Share | $0.83 |
| Equity (Book Value) | 5.46M |
| Book Value Per Share | 1.31 |
| Working Capital | 4.22M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$4.56 million and capital expenditures -$603,890, giving a free cash flow of -$5.17 million.
| Operating Cash Flow | -4.56M |
| Capital Expenditures | -603,890 |
| Free Cash Flow | -5.17M |
| FCF Per Share | -$1.19 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -97,344.76% |
| Pretax Margin | -97,992.31% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
VRAX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -85.92% |
| Shareholder Yield | -85.92% |
| Earnings Yield | -155.11% |
| FCF Yield | -132.24% |
Analyst Forecast
The average price target for VRAX is $3.00, which is 233.33% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.00 |
| Price Target Difference | 233.33% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 18, 2023. It was a reverse split with a ratio of 0.1:1.
| Last Split Date | Dec 18, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.1:1 |
Scores
VRAX has an Altman Z-Score of -3.62 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.62 |
| Piotroski F-Score | 1 |
